Physician profile
Lori King
NPI 1427578855
$2,186.56
in general payments reported to CMS, 2019-2025
21 companies · $605 in 2025
The $605 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.14 · 2022: $104 · 2023: $674 · 2024: $765 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $320.67 | 2023-2024 | Xarelto |
| Pfizer INC. | $239.71 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $215.64 | 2023-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $206.54 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $166.44 | 2023-2025 | |
| United Therapeutics Corporation | $158.74 | 2022-2025 | Tyvaso |
| Novo Nordisk INC | $142.08 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $130.68 | 2021-2025 | Farxiga, Brilinta |
| Philips North America LLC | $102.04 | 2023-2024 | (Cm9) Amb Mon & Diag Und, (5091) Amb Mon & Diag Und |
| Inspire Medical Systems, INC. | $100.00 | 2025 | Inspire |
| Boston Scientific Corporation | $74.73 | 2023-2024 | Bodyguardian, Watchman Flx, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.69 | 2023-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $53.13 | 2023-2024 | Opsumit, Uptravi |
| Amgen INC. | $52.00 | 2023-2024 | Repatha |
| Regeneron Healthcare Solutions, INC. | $36.68 | 2025 | Evkeeza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $35.37 | 2023-2024 | Inpefa |
| Abbott Laboratories | $23.84 | 2025 | Cardiomems |
| Lilly USA, LLC | $20.42 | 2025 | Zepbound |
| Glaxosmithkline, LLC. | $16.85 | 2024 | Arexvy, Trelegy Ellipta |
| Impulse Dynamics (USA) INC. | $15.82 | 2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $14.49 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.